Cutera (NASDAQ:CUTR) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cutera (NASDAQ:CUTRGet Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Stock Up 24.1 %

Shares of CUTR opened at $0.48 on Friday. Cutera has a 52 week low of $0.28 and a 52 week high of $4.97. The stock has a market cap of $9.77 million, a P/E ratio of -0.07 and a beta of 1.31. The business’s 50 day moving average price is $0.41 and its 200-day moving average price is $0.80.

Hedge Funds Weigh In On Cutera

Several large investors have recently modified their holdings of CUTR. Ground Swell Capital LLC bought a new stake in Cutera during the 2nd quarter valued at about $37,000. Squarepoint Ops LLC grew its holdings in shares of Cutera by 164.5% during the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of Cutera by 14.2% during the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after acquiring an additional 35,248 shares in the last quarter. Hedge funds and other institutional investors own 90.70% of the company’s stock.

About Cutera

(Get Free Report)

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.

Featured Stories

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.